Clinical trials: Cancer, Bladder
Urinary Bladder Neoplasms, Uterine Cervical Neoplasms
Effect of Pelvic Radiotherapy on the Intestinal Microbiome and Metabolome
Eight in ten patients will develop bowel problems during radiotherapy, eg diarrhoea, pain and incontinence, half will develop difficult long-term bowel problems.
- Conditions
- Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms
- Trial name
- EPRIMM (NCT04995809)
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- The Christie NHS Foundation Trust
Toxicity
Adjuvant Radiotherapy After Cystectomy for Muscle Invasive Bladder Cancer
A radical cystectomy + extended pelvic lymph node dissection is considered to be the treatment of choice for patients with muscle invasive bladder cancer (MIBC).
- Trial name
- NCT02397434
- Testing
- Adjuvant EBRT
- Where
- Belgium
- Volunteers
- 76 people
- Sponsor
- University Hospital, Ghent
Muscle Invasive Bladder Cancer (MIBC)
Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC
The goal of this clinical trial is to learn if oral probiotics (Clostridium butyricum) work to improve the efficacy of targeted therapy plus immunotherapy in bladder preservation setting for cisplatin-ineligible T2-3N0M0 bladder…
- Trial name
- NCT07474064
- Testing
- Probiotic, Disitamab Vedotin, Toripalimab
- Where
- China
- Volunteers
- 146 people
- Sponsor
- chenxu
Bladder Cancer
Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay
The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer.
- Trial name
- NCT05643690
- Testing
- UriFind Bladder Cancer Assay
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- AnchorDx Medical Co. Ltd. US
Invasive Bladder Cancer Stage II
Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy
This study aims to evaluate the effects of rapamycin directly on bladder tumors and the effects of rapamycin on the immune system of patients with bladder cancer.
- Trial name
- NCT01827618
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Non-Invasive Papillary Carcinoma of Bladder
ONCOFID-P-B in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder.
The purpose of the study is to assess, at control visit (V8), the ablative activity of intravesical administration of Oncofid-P-B on a papillary marker tumor on patients suffering from multiple primary and recurrent Ta G1-G2…
- Trial name
- NCT04661826
- Testing
- Oncofid-P-B
- Where
- 14 sites in Germany, Italy and 1 more
- Volunteers
- 60 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Urologic Diseases, Prostate Cancer
Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention
A study looking at the feasibility of doing a full-scale RCT that investigates the use of tranexamic acid intravesically prior to continuous bladder irrigation treatment in the emergency department for urinary retention due to…
- Conditions
- Urologic Diseases, Prostate Cancer, Bladder Cancer, Urinary Retention
- Trial name
- NCT04555343
- Testing
- Tranexamic acid
- Where
- 2 sites in Canada
- Volunteers
- 14 people
- Sponsor
- Fraser Health
Neuromuscular Blockade
Neuromuscular Blockade During Transurethral Resection of Bladder Cancer
Transurethral resection of the bladder tumor (TURB) for bladder tumor excision is the mainstream treatment. However, the beneficial effects of sugammadex after general anesthesia for TURB have not been thoroughly evaluated.
- Trial name
- NCT03039543
- Testing
- Rocuronium, Sugammadex
- Where
- South Korea
- Volunteers
- 108 people
- Sponsor
- Seoul National University Bundang Hospital
Cancer
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
This study will examine the efficacy and safety of lapatinib in patients with ErbB2 positive ovarian, gastric/esophageal adenocarcinoma, uterine serous papillary, or bladder cancers.
- Trial name
- NCT00447226
- Where
- 20 sites in United States
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Breast Cancer, Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)
Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors
This study looks at better ways to measure how tumors respond to treatment before surgery. Today, doctors often use RECIST 1.1 (Response Evaluation Criteria in Solid Tumors), which measures the longest diameter across a tumor on…
- Conditions
- Breast Cancer, Pancreatic Adenocarcinoma (Ductal Adenocarcinoma), Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)
- Trial name
- NCT07319767
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Zhongshan Hospital
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Carcinoma of Urinary Bladder, Superficial
Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer
The aim of the study is to test the value of immediate post-operative intravesical instillation of epirubicin in patients with intermediate and high risk non muscle invasive bladder cancer (NMIBC).
- Trial name
- NMIBCIVT (NCT02214602)
- Testing
- Epirubicin
- Where
- Egypt
- Volunteers
- 240 people
- Sponsor
- Mansoura University
Cystoscope, Bladder Cancer
Single-use Cystoscope System for Direct Visualization of the Urethra and Bladder
In this study, the new aScope 4 Cysto is used to see how well it visualizes the lower urinary tract, and if this new flexible cystoscope performs as well as other routinely used cystoscopes.
- Conditions
- Cystoscope, Bladder Cancer, Lower Urinary Tract Symptoms
- Trial name
- NCT04190641
- Testing
- Ambu aScope 4 Cysto and aView Urologia
- Where
- Denmark
- Volunteers
- 4 people
- Sponsor
- Ambu A/S
Bladder Cancer, Non-muscle Invasive Bladder Cancer
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
Blue light cystoscopy (BLC) is a diagnostic procedure in bladder cancer where the inside of the bladder is observed with a camera to detect bladder lesions.
- Trial name
- ENAiBLE (NCT07144319)
- Where
- 12 sites in United States, Belgium and 3 more
- Volunteers
- 500 people
- Sponsor
- Photocure
Bladder Cancer
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
This is a single-arm, multicenter study to evaluate the efficacy and safety of HX008 injection in patients with BCG-unresponsive non-muscle invasive bladder cancer.
- Trial name
- NCT04738630
- Testing
- HX008
- Where
- 5 sites in China
- Volunteers
- 110 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Neoplasm of Lateral Wall of Urinary Bladder
Safety Study of Bipolar Versus Monopolar Transurethral Resection of Bladder Tumors
This is a single-center, prospective, randomized, controlled trial comparing two established transurethral electrical resection methods of urinary bladder tumors regarding their risk of stimulating the obturator nerve.
- Trial name
- NCT01446822
- Testing
- Bipolar transurethral resection of the urinary bladder (PlasmaKinetic, Gyrus, Fresenius), Monopolar transurethral resection of the urinary bladder (Storz GmbH &Co., Erbotom, Purisole)
- Where
- Switzerland
- Volunteers
- 44 people
- Sponsor
- Daniel Stephan Engeler
Urothelial Carcinoma, Bladder Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy…
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult, Chemotherapy-induced Neutropenia
- Trial name
- PRESERVE3 (NCT04887831)
- Testing
- Trilaciclib, Gemcitabine, Cisplatin
- Where
- 34 sites in United States, France and 3 more
- Volunteers
- 92 people
- Sponsor
- G1 Therapeutics, Inc.
Urinary Bladder Neoplasms
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
A study to evaluate the safety and tolerability of nivolumab or nivolumab Plus BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer.
- Trial name
- CheckMate 9UT (NCT03519256)
- Testing
- Nivolumab, BCG, BMS-986205
- Where
- 88 sites in United States, Argentina and 13 more
- Volunteers
- 142 people
- Sponsor
- Bristol-Myers Squibb
Bladder Cancer
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00234039
- Testing
- gemcitabine hydrochloride
- Where
- 98 sites in United States
- Volunteers
- 58 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer, Urologic Cancer
Unmet Supportive Care Needs in Bladder Cancer Patients Undergoing Radical Cystectomy
Nowadays, high-quality cancer care is more than just diagnosis and treatment of cancer. Healthcare must respond to the specific needs of the patients to provide patient-centered care.
- Conditions
- Bladder Cancer, Urologic Cancer, Surgery
- Trial name
- NCT03307200
- Where
- 2 sites in Belgium
- Volunteers
- 90 people
- Sponsor
- University Hospital, Ghent
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.